4 completed, 1 active not recruiting, 1 terminated, 1 unknown. 7 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 7 | Completed 4, Active not recruiting 1, Terminated 1, Unknown 1 |
| Phase 2 | 1 | Unknown 1 |
Follow Generalized Pustular Psoriasis: new trials by email Literature Review of Generalized Pustular Psoriasis trials Research Report on Generalized Pustular Psoriasis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis HB0034 - Generalized Pustular Psoriasis | Phase 2 / Phase 3 | Unknown | Shanghai Huaota Biopharmaceutical Co., Ltd. | 33 | 2024-09-02 | 2025-02-14 |
| A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis TAK-279 - Generalized Pustular Psoriasis, Erythrodermic Psoriasis | Phase 3 | Completed | Takeda | 18 | 2024-03-19 | 2026-11-04 |
| A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis JNJ-77242113 - Generalized Pustular Psoriasis, Erythrodermic Psoriasis | Phase 3 | Active not recruiting | Janssen Pharmaceutical K.K. | 19 | 2024-02-09 | 2026-09-28 |
| Study to Evaluate the Long-Term Safety and Efficacy of Imsidolimab (ANB019) in the Treatment of Subjects With GPP Double-blind 200 mg imsidolimab, Placebo, Open-label 200 mg imsidolimab - Generalized Pustular Psoriasis | Phase 3 | Terminated | Vanda Pharmaceuticals | 42 | 2022-04-21 | 2026-03-27 |
| Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP 750 mg Imsidolimab, 300 mg Imsidolimab, Placebo - Generalized Pustular Psoriasis | Phase 3 | Completed | Vanda Pharmaceuticals | 45 | 2022-04-14 | 2026-03-17 |
| An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options spesolimab - Generalized Pustular Psoriasis | Phase 3 | Completed | Boehringer Ingelheim | 39 | 2022-03-15 | 2025-10-20 |
| An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options spesolimab - Generalized Pustular Psoriasis | Phase 3 | Completed | Boehringer Ingelheim | 11 | 2022-02-17 | 2025-02-25 |
Psoriasis (7)
Skin Diseases (7) · Skin Diseases, Papulosquamous (7) · Skin and Connective Tissue Diseases (7)
spesolimab (2) · Double-Blind Method (1) · Standard of Care (1)
Boehringer Ingelheim (2) · Vanda Pharmaceuticals (2) · Janssen Pharmaceutical K.K. (1) · Shanghai Huaota Biopharmaceutical Co., Ltd. (1) · Takeda (1)
Japan (3) · Australia (2) · China (2) · France (2) · Georgia (2) · Germany (2) · Malaysia (2) · Morocco (2) · Poland (2) · Romania (2) · South Korea (2) · Spain (2) · Taiwan (2) · Thailand (2) · Tunisia (2)